Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV003213760 | SCV003912712 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-12-18 | criteria provided, single submitter | clinical testing | The p.F944L variant (also known as c.2832C>G), located in coding exon 22 of the POLD1 gene, results from a C to G substitution at nucleotide position 2832. The phenylalanine at codon 944 is replaced by leucine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005021859 | SCV005650320 | uncertain significance | Colorectal cancer, susceptibility to, 10; Mandibular hypoplasia-deafness-progeroid syndrome; Immunodeficiency 120 | 2024-04-13 | criteria provided, single submitter | clinical testing |